Dallas, Texas 05/28/2014 (FINANCIALSTRENDS) – Dyax Corp. (NASDAQ:DYAX) is engaged in the development of a drug, having similar pathway to that of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX)’s OPuS-1 study candidate BCX4161, for the treatment of hereditary angioedema which a rare swelling disorder. Biocryst yesterday reported positing findings from its BCX4161 related proof of concept study. Equity experts at investment research firm Jefferies commented that the success of Biocryst’s OPuS-1 study allows to consider “higher odds for the success” of DX-2930 which is having a similar pathway. The analysts maintain a “buy” rating for the stock with a price target of $13. BioCryst reported an average rate of 1.27 attacks per week for patients on placebo as compared to 0.82 for those given BCX4161 orally.
Dyax Corp. (NASDAQ:DYAX)’s DX-2930 is currently in a Phase I trial and require to be administered intravenously twice a month against BioCryst’s BCX4161 which is an oral capsule. However, both the treatments offer potentials over the existing treatments which generally require intravenous administration every three to four days.
Equity analysts at BofA Merrill Lynch recently reaffirmed their “buy” rating for the stock of Dyax Corp. with a price target of $9. The analysts recently initiated coverage for this stock on April 22, 2014 and reaffirmed their rating and price target again on Friday, May 23, 2014. Equity analysts at research firm Leerink Swann significantly reduced their price target for the stock to $7, from previously held target price of $12 in a research note issued at the start of this month. The Leerink Swann analysts now maintain a “market perform” rating.
The stock of Dyax Corp. (NASDAQ:DYAX) has been assigned a “buy” rating by six analysts; and a “hold” rating by one analyst. The stock currently has a consensus rating of “buy” with an average price target of $11.33.
Yesterday, the stock gained 27.42% and closed at $8.41. The stock traded with significant volume of 6.39 million shares as compared to its average volume of 1.41 million shares.
This report is for information purposes only, and is neither a solicitation or recommendation to buy nor an offer to sell securities. Financials Trend is not-a-registered-investment-advisor. Financials Trend is not a broker-dealer. Information, opinions and analysis contained herein are based on sources believed to be reliable, but no representation, expressed or implied, is made as to its accuracy, completeness or correctness. The opinions contained herein reflect our current judgment and are subject to change without notice. Financials Trend accepts no liability for any losses arising from an investor's reliance on the use of this material. Financials Trend sometimes gets compensated up to one hundred and fifty thousand dollars per month for featuring particular stocks. See site disclaimer for complete compensation. Financials Trend and its affiliates or officers currently hold no shares of these stocks. Financials Trend and its affiliates or officers will purchase and sell shares of common stock of these stocks, in the open market at any time without notice. Financials Trend will not update its purchases and sales of these stocks in any future postings on Financials Trend's websites. Certain information included herein is forward-looking within the context of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements concerning manufacturing, marketing, growth, and expansion. The words "may", "would," "will," "expect," "estimate," "anticipate," "believe," "intend," " project," and similar expressions and variations thereof are intended to identify for ward-looking statements. Such forward- looking information involves important risks and uncertainties that could affect actual results and cause them to differ materially from expectations expressed herein. *Financials Trend does not set price targets on securities. Never invest into a stock discussed on this web site or in this email alert unless you can afford to lose your entire investment.